Virtus LifeSci Biotech Clinical Trials ETF
17 hedge funds and large institutions have $7.99M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Holders
17
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$309K | |
| 2 | +$286K | |
| 3 | +$228K | |
| 4 |
Jane Street
New York
|
+$109K |
| 5 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$56.3K |
Top Sellers
| 1 | -$426K | |
| 2 | -$365K | |
| 3 | -$96.9K | |
| 4 |
Goldman Sachs
New York
|
-$51.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$23.3K |